Interview with Mr. Wayne Fritzsche, Chairman of the Board for Pressure BioSciences, Inc. (OTCBB:PBIO) from the NIBA Conference in Las Vegas, NV.About Pressure BioSciences Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 24 issued patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.Forward Looking StatementsStatements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the advantages of PCT in processing samples from oil reservoirs and oil plumes, including the extraction of significantly more nucleic acids and proteins than other available methods, and the extraction of a greater microbial diversity from such samples; that improved microbe analysis may lead to better strategies for oil spill clean-up; the use of natural microorganisms to degrade oil before it accumulates; the number of laboratories performing studies similar to the scientists at LBNL; and the additional sales opportunities that may result from the collaboration with LBNL. These statements are based upon PBI's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties, delays and additional costs in the implementation of PBI's strategies that may adversely affect the commercialization of PCT and PCT-dependent products, including PBI's plan to focus on laboratories performing studies similar to LBNL; the collaboration with LBNL may not result in generating data that supports the advantages of PCT for microbe analysis, and LBNL continuing with the reagent rental program after the initial six-month period; changes in customer needs and technological innovations; other scientists may not achieve the same PCT results reported by LBNL; and PBI's sales force may not successfully sell the PCT product line because scientists may not perceive the advantages of PCT for releasing proteins and nucleic acids in microorganisms in oil reservoirs and oil plumes. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the first quarter of 2011. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in PBI's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by PBI from time to time with the SEC. PBI undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Less